AbbVie (4AB) Stock Forecast & Price Target

Compare

24 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4AB Analyst Ratings

Moderate Buy

15 Buy

7 Hold

0 Sell

Based on 22 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4AB Stock 12 Month Forecast

Average Price Target

€208.06

▲(7.03% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is €208.06 with a high forecast of €244.01 and a low forecast of €174.42. The average price target represents a 7.03% change from the last price of €194.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"158":"€158","245":"€245","179.75":"€179.8","201.5":"€201.5","223.25":"€223.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":244.00994296,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€244.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":208.0614358704,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€208.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":174.41555782,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€174.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[158,179.75,201.5,223.25,245],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,203.029,206.1813802276923,209.3337604553846,212.4861406830769,215.63852091076922,218.79090113846152,221.94328136615383,225.09566159384616,228.24804182153846,231.40042204923077,234.55280227692307,237.70518250461538,240.85756273230768,{"y":244.00994296,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,203.029,203.41611045156924,203.80322090313845,204.1903313547077,204.5774418062769,204.96455225784615,205.3516627094154,205.7387731609846,206.12588361255385,206.5129940641231,206.9001045156923,207.28721496726155,207.67432541883076,{"y":208.0614358704,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,203.029,200.82796598615386,198.6269319723077,196.42589795846155,194.22486394461538,192.02382993076924,189.82279591692307,187.62176190307693,185.42072788923076,183.21969387538462,181.01865986153845,178.8176258476923,176.61659183384614,{"y":174.41555782,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":170.917,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.734,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.992,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.268,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.314,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.814,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.791,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.727,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.837,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.443,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.189,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.918,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.029,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€244.01

Average Price Target€208.06

Lowest Price Target€174.42

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

€244.01

Buy

25.52%

Upside

Reiterated

10/28/25

Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)

Luisa Hector

Berenberg Bank

€231.98

Buy

19.33%

Upside

Reiterated

10/27/25

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Asad Haider

Goldman Sachs

€186.44→€187.3

Hold

-3.65%

Downside

Reiterated

10/23/25

AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges

Veda Pharmyne

TR | OpenAI - 4o

€195.9→€213.08

Hold

9.61%

Upside

Reiterated

10/22/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

€174.42

Hold

-10.28%

Downside

Assigned

10/21/25

Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)

Tim Anderson

Bank of America Securities

€215.66

Hold

10.93%

Upside

Reiterated

10/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Alpha Cognition Inc (NASDAQ: ACOG) and Exelixis (NASDAQ: EXEL)

Vamil Divan

Guggenheim

€195.04→€207.92

Buy

6.96%

Upside

Reiterated

10/19/25

Guggenheim Sticks to Their Buy Rating for AbbVie (ABBV)

Gary Nachman

Raymond James

€202.77→€214.8

Buy

10.49%

Upside

Reiterated

10/17/25

AbbVie price target raised to $250 from $236 at Raymond JamesAbbVie price target raised to $250 from $236 at Raymond James

Mohit Bansal

Wells Fargo

€223.39

Buy

14.91%

Upside

Reiterated

10/14/25

Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)

Geoff Meacham

Citi

―

Hold

―

Reiterated

10/14/25

Citi Sticks to Their Hold Rating for AbbVie (ABBV)

Carter Gould

Cantor Fitzgerald

€214.8

Buy

10.49%

Upside

Reiterated

10/14/25

Cantor Fitzgerald Sticks to Its Buy Rating for AbbVie (ABBV)Cantor Fitzgerald Notes IPRD Charge Impact on Abbvies (ABBV) 3Q EPS

Jeffrey La Rosa

Leerink Partners

€208.78

Buy

7.40%

Upside

Reiterated

10/14/25

Leerink Partners Keeps Their Buy Rating on AbbVie (ABBV)

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/13/25

AbbVie downgraded to Hold from Buy at Erste GroupAbbVie downgraded to Hold from Buy at Erste Group

Chris Schott

J.P. Morgan

€201.91→€214.8

Buy

10.49%

Upside

Reiterated

10/09/25

Analysts Offer Insights on Healthcare Companies: Compugen (NASDAQ: CGEN) and AbbVie (NYSE: ABBV)

Rajesh Kumar

HSBC

€180.43→€193.32

Hold

-0.56%

Downside

Downgraded

10/01/25

AbbVie downgraded to Hold from Buy at HSBCAbbVie downgraded to Hold from Buy at HSBC

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

€244.01

Buy

25.52%

Upside

Reiterated

10/28/25

Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)

Luisa Hector

Berenberg Bank

€231.98

Buy

19.33%

Upside

Reiterated

10/27/25

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Asad Haider

Goldman Sachs

€186.44→€187.3

Hold

-3.65%

Downside

Reiterated

10/23/25

AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges

Veda Pharmyne

TR | OpenAI - 4o

€195.9→€213.08

Hold

9.61%

Upside

Reiterated

10/22/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

€174.42

Hold

-10.28%

Downside

Assigned

10/21/25

Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)

Tim Anderson

Bank of America Securities

€215.66

Hold

10.93%

Upside

Reiterated

10/20/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Alpha Cognition Inc (NASDAQ: ACOG) and Exelixis (NASDAQ: EXEL)

Vamil Divan

Guggenheim

€195.04→€207.92

Buy

6.96%

Upside

Reiterated

10/19/25

Guggenheim Sticks to Their Buy Rating for AbbVie (ABBV)

Gary Nachman

Raymond James

€202.77→€214.8

Buy

10.49%

Upside

Reiterated

10/17/25

AbbVie price target raised to $250 from $236 at Raymond JamesAbbVie price target raised to $250 from $236 at Raymond James

Mohit Bansal

Wells Fargo

€223.39

Buy

14.91%

Upside

Reiterated

10/14/25

Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)

Geoff Meacham

Citi

―

Hold

―

Reiterated

10/14/25

Citi Sticks to Their Hold Rating for AbbVie (ABBV)

Carter Gould

Cantor Fitzgerald

€214.8

Buy

10.49%

Upside

Reiterated

10/14/25

Cantor Fitzgerald Sticks to Its Buy Rating for AbbVie (ABBV)Cantor Fitzgerald Notes IPRD Charge Impact on Abbvies (ABBV) 3Q EPS

Jeffrey La Rosa

Leerink Partners

€208.78

Buy

7.40%

Upside

Reiterated

10/14/25

Leerink Partners Keeps Their Buy Rating on AbbVie (ABBV)

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/13/25

AbbVie downgraded to Hold from Buy at Erste GroupAbbVie downgraded to Hold from Buy at Erste Group

Chris Schott

J.P. Morgan

€201.91→€214.8

Buy

10.49%

Upside

Reiterated

10/09/25

Analysts Offer Insights on Healthcare Companies: Compugen (NASDAQ: CGEN) and AbbVie (NYSE: ABBV)

Rajesh Kumar

HSBC

€180.43→€193.32

Hold

-0.56%

Downside

Downgraded

10/01/25

AbbVie downgraded to Hold from Buy at HSBCAbbVie downgraded to Hold from Buy at HSBC

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+4.32%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +4.32% per trade.

3 Months

xxx

Success Rate

20/27 ratings generated profit

Average Return

+7.79%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 74.07% of your transactions generating a profit, with an average return of +7.79% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

17/17 ratings generated profit

Average Return

+21.45%

reiterated a buy rating 2 months ago

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.45% per trade.

2 Years

xxx

Success Rate

28/28 ratings generated profit

Average Return

+33.85%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4AB Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4AB has received 33 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. 4AB average Analyst price target in the past 3 months is 208.06.

Each month's total comprises the sum of three months' worth of ratings.

4AB Financial Forecast

4AB Earnings Forecast

Next quarter’s earnings estimate for 4AB is €1.52 with a range of €1.44 to €1.62. The previous quarter’s EPS was €2.56. 4AB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 4AB has Preformed in-line its overall industry.

4AB Sales Forecast

Next quarter’s sales forecast for 4AB is €13.42B with a range of €13.24B to €13.68B. The previous quarter’s sales results were €13.28B. 4AB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 4AB has Preformed in-line its overall industry.

4AB Stock Forecast FAQ

What is DE:4AB’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 208.06.

What is DE:4AB’s upside potential, based on the analysts’ average price target?

AbbVie has 7.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AbbVie a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.

What is AbbVie’s share price target?

The average share price target for AbbVie is 208.06. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €244.01 ,and the lowest forecast is €174.42. The average share price target represents 7.03% Increase from the current price of €194.4.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of AbbVie?

To buy shares of DE:4AB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (4AB) Stock Forecast & Price Target

4AB Analyst Ratings

4AB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

4AB Analyst Recommendation Trends

4AB Financial Forecast

4AB Earnings Forecast

4AB Sales Forecast

4AB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts